Harrow Inc   (HROW)
Other Ticker:  
Price: $10.9500 $0.13 1.155%
Day's High: $11 Week Perf: -2.84 %
Day's Low: $ 10.68 30 Day Perf: 14.9 %
Volume (M): 176 52 Wk High: $ 28.25
Volume (M$): $ 1,927 52 Wk Avg: $16.10
Open: $10.83 52 Wk Low: $7.60

 Market Capitalization (Millions $) 375
 Shares Outstanding (Millions) 34
 Employees 257
 Revenues (TTM) (Millions $) 114
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) 21
 Capital Exp. (TTM) (Millions $) 2

Harrow Inc
Harrow Health Inc is a publicly-traded, US-based company that specializes in designing, developing and marketing branded prescription and over-the-counter (OTC) pharmaceutical products. The company was founded in 2017 and is headquartered in Nashville, Tennessee. Harrow Health is led by its CEO, Mark L. Baum, who has over 30 years of experience in the pharmaceutical industry.

The company's business model is centered around the development and commercialization of high-quality, affordable and innovative drug products. Harrow Health focuses primarily on niche markets, targeting pharmaceuticals that are used to treat underserved diseases and conditions. The company has an experienced team of medical professionals, researchers and executives who are committed to driving growth through a blend of branded and generic drug products.

Harrow Health's portfolio includes FDA-approved branded drugs and OTC products for the treatment of hypothyroidism, glaucoma, insomnia, and diminished sex drive among others. The company also has a strong pipeline of products under development, including products targeting dry eye disease, neuropathic pain, and acute migraines.

One of Harrow Health's key strengths is its proprietary technologies - the company has developed unique systems for manufacturing and delivering medications that improve efficiency, reduce waste and reduce overall production costs. This allows Harrow Health to offer its products at competitive prices while maintaining high margins and profitability.

Harrow Health operates through its subsidiaries, ImprimisRx and Park Compounding. ImprimisRx is a compounding pharmacy that specializes in preparing customized medications for patients with specific medical needs. Park Compounding, on the other hand, is focused on developing and testing new formulations, with the goal of improving the effectiveness and tolerability of existing drugs.

Harrow Health's growth strategy includes both organic growth and acquisitions. The company is actively pursuing acquisitions of other pharmaceutical companies and assets that align with its business model and strategic objectives. In addition, Harrow Health is focused on expanding its product offerings and leveraging its existing technologies to launch new products for underserved markets.

Overall, Harrow Health is a dynamic and rapidly-growing pharmaceutical company that is committed to bringing innovative and affordable products to market. With a strong leadership team, proprietary technologies and a robust product pipeline, the company is poised for continued success in the years ahead.

   Company Address: 102 Woodmont Blvd. Nashville 37205 TN
   Company Phone Number: 733-4730   Stock Exchange / Ticker: NASDAQ HROW
   HROW is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season

As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.

Harrow Health Inc

Title: Harrow Health Inc Strong Performance Despite Recent Stock Dip

Harrow Health Inc, a pharmaceutical company trading on the NASDAQ, has recently experienced a drop in its stock price, falling by -7.54% over the past seven days. Despite this decrease, the company's year-to-date performance remains strong, with a 33.96% increase. Additionally, the stock is currently trading 26.1% above its 52-week average.
Looking at the financial performance of Harrow Health Inc for the April to June 30, 2023, period, there are several notable highlights. The company managed to decrease its loss per share from $-0.23 to $-0.14 compared to the same period last year. Furthermore, the earnings per share (EPS) improved from $-0.22 in the prior reporting period.

Harrow Health Inc

Harrow Health Inc Surprises with Striking Business Improvement, Sets Stage for Promising Future

Despite a loss per share and a decrease in EPS for the fiscal first quarter of 2023, Harrow Health Inc. is still a promising company to watch out for in the years to come. The company's revenue grew significantly by 18.006% to $26.10 million compared to the previous year, and sequentially revenue improved by a staggering 28.403% from $20.33 million.
Despite the net loss of $-6.643 million, the company's operating earnings only fell -42.41% to $1.21 million. Although this has squeezed Harrow Health Inc.'s operating margin to 4.64% from 9.5% in the first quarter of 2022, it is still noteworthy that the company has rebounded despite the challenges of the past year.


Harrow Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com